HPV IMPACT |
16053
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-16053,ajax_fade,page_not_loaded,,qode-title-hidden,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Studying

The study begins with collecting the necessary data and swabs. This is all that is required to generate the information we need.

Measuring

We take the data we have collected and analyse it to see patterns and outcomes that can be attributed to the HPV vaccine.

Reporting

We report the results for how successful the HPV vaccine in Australia has been. These results can change peoples lives and inform government and policy.

Understanding the HPV Vaccine

Human papillomavirus (HPV) is a very common sexually transmitted virus that affects men and women. It usually causes no symptoms and goes away by itself, but in some cases it can lead to serious health conditions such as pre-cancer, and if not treated can lead to cervical cancer in women, and penile and anal cancer in men.

A nonavalent vaccine called Gardasil 9 has been developed that protects against the seven oncogenic HPV types (types 16, 18, 31, 33, 45, 52 and 58), which cause 90% of cervical cancers in women and HPV related cancers in men. It also protects against two low-risk HPV types (types 6 and 11), which cause 90% of genital warts. This vaccine is provided by the Australian Government free of charge for girls and boys aged 12-13.

The IMPACT study will monitor how well the National HPV Vaccination Program is working by measuring how common the HPV virus is now, in healthy men and women. In the coming years, reports and research outputs providing information about the study and our findings will be posted here.

During 2014-2018 we recruited participants through a network of Family Planning, Sexual Health, General Practice Clinics, and Aboriginal Medical Services throughout Australia. From 2019, we are employing several strategies to best assess the impact of the vaccine among different populations of interest. The introduction of primary HPV testing with partial genotyping, provides an opportunity to integrate monitoring of both the screening and vaccination programs among women participating in cervical screening. This system is complemented with targeted sentinel surveillance using residual clinical samples submitted for routine STI testing in specific Australian populations, (such as women under the age of 25, and men who have sex with men) to provide comprehensive epidemiological surveillance of HPV vaccine impact in Australia.

Recent News

  • Julie Leask, Associate Professor at The University of Sydney, School of Public Health discusses vaccination hesitancy and “anti-vaxxers”...

  • Associate Professor Julia Brotherton, an epidemiologist and Medical Director, discusses the latest finding from the program...

  • A useful fact sheet providing information on HPV disease and the available vaccines...

The Importance of the Study